NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

NewAmsterdam Pharma Company N.V.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on NewAmsterdam Pharma Company (NAMS), Insmed (INSM) an...

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Shattuck Labs (STTK) and NewAmsterdam Pharma Company...

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on NewAmsterdam Pharma Company yesterday and set a price target of $52.00. Pantgin...

Market Cap	$3.94B	P/E Ratio	N/A
52W High	$42.21	52W Low	$16.79
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-21.5%	52W Position	77.9%
Overall Score	57	Value Score	50
Quality Score	55	Technical Score	66

EPS Current Est	$-1.76	EPS Next Est	$-1.14
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NAMS	$36.58	+1.29%	263.37K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NAMS	$36.58	+1.3%	263.37K
3
4
5
6

NAMS

NAMS

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get NewAmsterdam Pharma Company N.V. Data in Excel

Get NewAmsterdam Pharma Company N.V. Data in Excel